Bengaluru-based health-tech and longevity startup Biopeak has raised $2.7 million in a follow-on funding round led by NKSquared, the investment firm of Zerodha cofounder Nikhil Kamath.
This marks Kamath’s second bet on the company, after his earlier $1.43 million investment in August 2024.
The fresh capital will be used to expand Biopeak’s clinical footprint, including the launch of a new clinic, while also strengthening its diagnostics stack, proprietary AI tools, research efforts, and clinical programmes, the company said in a statement.
Founded by Rishi Pardal (CEO) and Shiva Subramanian (CIO) in 2024, Biopeak operates at the intersection of AI, advanced diagnostics, and preventive healthcare, with a sharp focus on healthspan optimisation, helping people stay healthier and high-performing for longer, rather than just treating illness.
Biopeak follows what it calls a “family health office” model, offering deeply personalized longevity plans built on AI-driven molecular diagnostics, imaging, and expert-led interventions.
Its platform integrates data from organic acid profiling, microbiome mapping, whole-exome functional genomics, salivary cortisol rhythms, and imaging tools such as MRI, CT, DXA, and ECHO. These insights are then translated into actionable recommendations around nutrition, sleep, stress, and performance through its in-house clinics.
The startup primarily targets high achievers, CXOs, and women navigating key health transitions, combining wearable data, specialist teams, and AI insights tailored specifically to Indian biology and disease patterns. The emphasis is on early risk detection, longitudinal tracking, and proactive interventions to improve resilience and long-term performance.
Over the past year, Biopeak has seen growing demand for structured longevity services. It opened its first clinic in Bengaluru last year and is set to launch a second clinic in the city in the coming month.
As of January 2026, Biopeak has raised approximately $11 million in total funding. Alongside NKSquared, its investor roster includes Prashanth Prakash (Accel India), Dr. Ranjan Pai (Claypond Capital), and Rainmatter, Zerodha’s investment arm. The company also works with Austria’s Modern Mayr Medicine, blending decades-old preventive health practices with modern AI-led care.
